Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 10, 2016 - Issue 1
Submit an article Journal homepage
314
Views
7
CrossRef citations to date
0
Altmetric
Drug profile

Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection

Vinay SundaramDepartment of Medicine and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA
&
Kris V. KowdleyCorrespondence[email protected]
Pages 13-20 | Published online: 02 Dec 2015

References

  • Papers of special note have been highlighted as:
  • * Of interest
  • ** Of considerable interest
  • Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N E J Med. 1999;341(8):556–562. DOI:10.1056/NEJM199908193410802.
  • Global Burden Of Hepatitis CWG. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44(1):20–29. DOI:10.1177/0091270003258669.
  • Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29(4):1311–1316. DOI:10.1002/hep.510290424.
  • Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl 2):30–60. DOI:10.1111/j.1478-3231.2011.02539.x.
  • Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–327. DOI:10.1002/hep.26744.
  • Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20(10):669–677. DOI:10.1111/jvh.12168.
  • Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol. 2007;46(6):999–1008. DOI:10.1016/j.jhep.2006.10.019.
  • Abid K, Pazienza V, de Gottardi A, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol. 2005;42(5):744–751. DOI:10.1016/j.jhep.2004.12.034.
  • Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33(6):1358–1364. DOI:10.1053/jhep.2001.24432.
  • Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33(1):106–115.
  • Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36(5):1266–1272. DOI:10.1053/jhep.2002.36370.
  • Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38(1):75–85. DOI:10.1053/jhep.2003.50267.
  • Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51(4):655–666. DOI:10.1016/j.jhep.2009.05.016.
  • Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18(10):e516–22. DOI:10.1111/j.1365-2893.2011.01441.x.
  • Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV. Hepatology. 2014;60(1):98–105. DOI:10.1002/hep.27095.
  • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N E J Med. 2002;347(13):975–982. DOI:10.1056/NEJMoa020047.
  • Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–1444. DOI:10.1002/hep.24641.
  • Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull. 2015;113(1):31–44. DOI:10.1093/bmb/ldv004.
  • Herbst DA Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs. 2013;22(4):527–536. DOI:10.1517/13543784.2013.775246.
  • Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N E J Med. 2013;368(20):1867–1877. DOI:10.1056/NEJMoa1214854.
  • Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N E J Med. 2013;369(7):678–679. DOI:10.1056/NEJMc1307641.
  • Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N E J Med. 2014;370(21):1993–2001. DOI:10.1056/NEJMoa1316145.
  • Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2015;42(3):258–272. DOI:10.1111/apt.13264.
  • Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135. DOI:10.1002/hep.27726.

** Of considerable importance as this is the first phase III study evaluating sofosbuvir and daclatasvir for hepatitis C virus genotype 3.

  • Hezode C, De Ledinghen V, Fontaine H, et al. LP05: daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program. J Hepatol. 2015;62:S265–S66. DOI:10.1016/S0168-8278(15)30159-8.

** Of considerable importance as this illustrates the benefits of extended therapy to 24 weeks of sofosbuvir and daclatasvir in patients with cirrhosis.

  • Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with HCV genotype 3 infection and treatment-experienced patients with cirrhosis and HCV genotype 2 infection. Gastroenterology. 2015. DOI:10.1053/j.gastro.2015.07.043.
  • Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61(3):769–775. DOI:10.1002/hep.27567.
  • Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434–441. DOI:10.1016/j.jhep.2013.04.035.
  • Rahimi RS, O’Leary JG. Post-liver transplant hepatitis C therapy. Curr Treat Options Gastroenterol. 2015;13(2):249–258. DOI:10.1007/s11938-015-0051-1.
  • Bahadi A, Maoujoud O, Zejjari Y, et al. Diagnosis and evaluation of hepatitis C virus among haemodialysis patients. East Mediterr Health J. 2013;19(2):192–199.
  • Fabrizi F, Dixit V, Messa P, et al. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Med Virol. 2010;82(5):768–775. DOI:10.1002/jmv.21542.
  • Liu CH, Huang CF, Liu CJ, et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med. 2013;159(11):729–738. DOI:10.7326/0003-4819-159-11-201312030-00005.
  • Herbst DA, Reddy KR. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs. 2013;22(10):1337–1346. DOI:10.1517/13543784.2013.826189.
  • Gu M, Rice CM. Structures of hepatitis C virus nonstructural proteins required for replicase assembly and function. Curr Opin Virol. 2013;3(2):129–136. DOI:10.1016/j.coviro.2013.03.013.
  • Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol. 2013;3(5):514–520. DOI:10.1016/j.coviro.2013.06.014. .
  • Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013;110(10):3991–3996. DOI:10.1073/pnas.1203110110.
  • McCormack PL. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection. Drugs. 2015;75(5):515–524. DOI:10.1007/s40265-015-0362-5.
  • Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 2011;54(6):1956–1965. DOI:10.1002/hep.24609.
  • European Medicines Agency. Daklinza (daclatasvir dihydrochloride): summary of product characteristics. 2014. [ cited 2015 Aug 31]. HCV GT3 review-Sundaram revision.docx.
  • Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465(7294):96–100. DOI:10.1038/nature08960.
  • Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N E J Med. 2014;370(3):211–221. DOI:10.1056/NEJMoa1306218.
  • Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N E J Med. 2015;373(8):714–725. DOI:10.1056/NEJMoa1503153.
  • Coilly A, Fougerou C, De Ledinghen V, et al. G15: the association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: results from a large French prospective multicentric ANRS CO23 CUPILT cohort. J Hepatol. 2015;62:S236–S237. DOI:10.1016/S0168-8278(15)30103-3.
  • Welzel TM, Herzer K, Ferenci P, et al. P0772: daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program. J Hepatol. 2015;62:S619–S620. DOI:10.1016/S0168-8278(15)30975-2.
  • Nakamoto S, Kanda T, Wu S, et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014;20(11):2902–2912. DOI:10.3748/wjg.v20.i11.2902.
  • Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18(7):931–940. DOI:10.3851/IMP2674.
  • (EASL) TEAftSotL. Recommendations on treatment of hepatitis C. 2015

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.